Jul 23 |
LEXX: GLP-1 Agonist Program Updates
|
Jul 18 |
Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations
|
Jul 17 |
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
|
Jul 16 |
Lexaria Preparing For Strategic Growth
|
Jul 9 |
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
|
Jul 8 |
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
|
Jun 18 |
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
|
Jun 5 |
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
|
Jun 4 |
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
May 17 |
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
|